Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Lenny Dang(Agios Pharmaceuticals (United States)), David W. White(Agios Pharmaceuticals (United States)), Stefan Größ(Agios Pharmaceuticals (United States)), Bryson D. Bennett(Princeton University), Mark Bittinger(Agios Pharmaceuticals (United States)), Edward M. Driggers(Agios Pharmaceuticals (United States)), Valeria R. Fantin(Agios Pharmaceuticals (United States)), Hyun Gyung Jang(Agios Pharmaceuticals (United States)), Shengfang Jin(Agios Pharmaceuticals (United States)), Marie C. Keenan(Agios Pharmaceuticals (United States)), Kevin M. Marks(Agios Pharmaceuticals (United States)), Robert M. Prins(UCLA Medical Center), Patrick S. Ward(University of Pennsylvania), Katharine Yen(Agios Pharmaceuticals (United States)), Linda M. Liau(UCLA Medical Center), Joshua D. Rabinowitz(Princeton University), Lewis C. Cantley(Beth Israel Deaconess Medical Center), Craig B. Thompson(University of Pennsylvania), Matthew G. Vander Heiden(Agios Pharmaceuticals (United States)), Shinsan M. Su(Agios Pharmaceuticals (United States))
Nature
November 22, 2009
10.1038/nature08617
Cited by 4,113Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis